- Entrectinib in Chinese (mainland China, Hong Kong, Taiwan) patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC and NTRK-fp solid tumoursLu, S.; Chiu, C-H.; Yu, Y.; Loong, H. H. F.; Lin, C. C.; Hu, X.; Dong, X.; Li, J.; Zhao, J.; Ye-Hui, S.; Zhang, Z.; Zhao, N.; Xia, J.; Wang, D.; Fan, Y.European Lung Cancer Congress (ELCC), ELECTR NETWORK, 2022-03-30 To 2022.
- Updated efficacy and safety data of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (fp) solid tumoursLu, S.; De Braud, F. G. M.; Fan, Y.; Hu, X.; Ohe, Y.; Yu, Y.; Ahn, M-J.; Cassier, P.; Lin, J. J.; Paz-Ares, L.; Xue, C.; Bordogna, W.; Patel, S.; Zeuner, H.; Dong, X.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, 2023-10-20 To 2023-10-24.
- Updated efficacy and safety of taletrectinib in patients ( pts) with ROS1+non-small cell lung cancer (NSCLC)Li, W.; Yang, N.; Li, K.; Fan, H.; Yu, Q.; Wu, H.; Wang, Y.; Meng, X.; Wu, J.; Wang, Z.; Liu, Y.; Wang, X.; Qin, X.; Lu, K.; Zhuang, W.; He, S.; Janne, P. A.; Seto, T.; Ou, S-H. I.; Zhou, C.
会议论文
Updated analysis of entrectinib in a subset of Chinese (mainland China, Hong Kong, Taiwan) patients (pts) with NTRK fusion-positive (fp) solid tumours and ROS1-fp nonsmall cell lung cancer (NSCLC)
3阅读
